다니스코뉴트리션앤드바이오싸이언스코리아

비상장계속사업자

Danisco Nutrition & Biosciences Korea Ltd.

비키 카팔티스(Vicki Kafaltis)

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

다니스코뉴트리션앤드바이오싸이언스코리아

Business Reg. No. 6238101776 · CEO 비키 카팔티스(Vicki Kafaltis)

I.Investment Overview

Target다니스코뉴트리션앤드바이오싸이언스코리아 (6238101776)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명다니스코뉴트리션앤드바이오싸이언스코리아
영문명Danisco Nutrition & Biosciences Korea Ltd.
대표자비키 카팔티스(Vicki Kafaltis)
사업자등록번호6238101776
법인등록번호1101140256435
설립일2020.02.28

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW186.72021351.82022350.42023403.420245012025
영업이익100M KRW18.8202160.7202232.3202319.6202447.92025
순이익100M KRW17.2202145.4202228.8202312.3202442.62025
Item20252024202320222021
자산총계270.5억원195억원225억원217.4억원125.3억원
부채총계105.8억원72.8억원115.1억원136.4억원89.7억원
자본총계164.7억원122.2억원109.9억원81.1억원35.6억원
매출액501억원403.4억원350.4억원351.8억원186.7억원
영업이익47.9억원19.6억원32.3억원60.7억원18.8억원
순이익42.6억원12.3억원28.8억원45.4억원17.2억원

VI.Financial Ratios

FY2025 basis

9.57%

영업이익률

8.5%

순이익률

15.74%

ROA

25.84%

ROE

64.21%

부채비율

60.9%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

다니스코뉴트리션앤드바이오싸이언스코리아 투심보고서 | Alpha Lenz